Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions

A scar, abnormal technology, applied in the field of treatment and inhibition of abnormal scar formation, can solve the problems of side effects, seriousness, recurrence, etc.
CN1668312AInactive Publication Date: 2005-09-14CHILDRENS HOSPITAL OF LOS ANGELES +1
0 Cites 14 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHILDRENS HOSPITAL OF LOS ANGELES
Publication Date
2005-09-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and / or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] related application

[0002] This application is based upon and claims the benefit of priority from US Provisional Application No. 60 / 380,696, filed March 13, 2002, and contains the entire contents thereof including the accompanying drawings.

[0003] Government funding

[0004] This invention was made with a grant from the National Academy of General Medicine (GM55081), and thus the US Government has certain rights in this invention in certain respects. field of invention

[0005] The present invention relates to the treatment and inhibition of abnormal scar formation, and more particularly, the present invention relates to reducing the activity of plasminogen activator inhibitor-1 during wound healing to reduce the excessive deposition of collagen, which can be Causes abnormal scarring, including keloids, hypertrophic scars, adhesions, and other skin or internal trauma or damage. Background of the invention

[0006] Wound healing is a continuous process that can g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More